A Novel Transcriptomic Classifier for AML Is Highly Associated with Drug Sensitivity

Introduction: AML is a heterogeneous disease with a wide array of common genetic aberrations. Traditional classification of AML leverages both classical cytogenetics and mutational profiling to stratify patients into four distinct risk groups (ELN). However, tumor gene expression profiles can play an important role in response to therapy, and are potentially useful for unravelling the heterogeneity of AML. In this study, we hypothesized that clinical outcomes and variable responses to therapeutic modalities in AML may be driven by patterns of gene expression, and sought to identify clinically actionable molecular subtypes using the available RNAseq data from the BEAT AML functional genomics study.